12 Month Price Forecast For MOLN
Distance to MOLN Price Forecasts
MOLN Price Momentum
๐ค Considering Molecular Partners (MOLN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 4:12 AM UTC
MOLN Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, MOLN has a consensus that is bullish. The median price target is $9.52, with forecasts ranging from $4.97 to $16.83. Currently, there are 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With MOLN currently trading at $4.97, the median price forecast suggests a 91.6% upside. The most optimistic forecast comes from at , projecting a 238.7% upside, while at provides the most conservative target, suggesting a 0.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MOLN Analyst Consensus
MOLN Price Target Range
Latest MOLN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MOLN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 5, 2023 | JP Morgan | Richard Vosser | Neutral | Maintains | $4.50 |
Aug 29, 2022 | SVB Leerink | Daina Graybosch | Market Perform | Downgrade | $8.00 |
May 25, 2022 | Credit Suisse | Dominic Lunn | Neutral | Upgrade | $0.00 |
Apr 27, 2022 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $29.00 |
Jan 14, 2022 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $42.00 |
Aug 27, 2021 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $35.00 |
Jul 13, 2021 | Cowen & Co. | Outperform | Initiates | $0.00 |
Stocks Similar to Molecular Partners AG
The following stocks are similar to Molecular Partners based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Molecular Partners AG (MOLN) Financial Data
Molecular Partners AG has a market capitalization of $183.21M with a P/E ratio of 1.7x. The company generates $6.60M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -73.2% quarter-over-quarter, while maintaining an operating margin of -2,142.3% and return on equity of -37.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Molecular Partners AG (MOLN) Company Overview
About Molecular Partners AG
Develops targeted therapeutics for oncology and virology.
The company operates as a clinical-stage biotechnology firm, generating revenue through the development of innovative therapeutics such as designed ankyrin repeat proteins (DARPins) aimed at treating cancer and viral diseases. It engages in licensing and collaboration agreements with major pharmaceutical companies, allowing it to leverage its specialized platforms for drug development.
Molecular Partners AG is currently advancing several promising candidates in clinical trials, including MP0317 and MP0533, which target specific immune responses in cancer treatment. The company also utilizes its unique Switch-DARPin and Radio-DARPin platforms to enhance therapeutic delivery and efficacy. Established in 2004 and based in Switzerland, the company has strategic partnerships with industry leaders like Novartis and Orano Med to further its research and development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
167
CEO
Dr. Patrick Amstutz Ph.D.
Country
Switzerland
IPO Year
2015
Website
www.molecularpartners.comMolecular Partners AG (MOLN) Latest News & Analysis
Molecular Partners AG is developing targeted cancer therapies with early-stage candidates MP0533 and MP0317. It has a cash runway of 2-2.5 years, but future funding is uncertain, posing sustainability risks.
Molecular Partners AG's innovative cancer therapies show promise, but uncertain future funding and early-stage risks may impact long-term viability, affecting investor confidence and stock performance.
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
26 days agoMolecular Partners AG has expanded its strategic collaboration with Orano Med, focusing on DARPin therapeutics and targeted alpha-particle therapies (TAT) with lead-212.
The expansion of the collaboration between Molecular Partners and Orano Med indicates potential advancements in innovative therapies, which could lead to increased market competitiveness and future revenue growth.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced key program updates and 2025 milestones to be presented at the J.P. Morgan Healthcare Conference on January 12, 2025.
Molecular Partners' update on development plans and milestones at a major healthcare conference signals potential growth and investment opportunities in the biotech sector.
Molecular Partners AG will present its developments and 2025 outlook at two investor conferences in January, highlighting its focus on DARPin therapeutics.
Molecular Partners' presentation at investor conferences signals potential insights into its pipeline and future growth, influencing investor sentiment and stock valuation.
Molecular Partners AG (MOLN) has a consensus price target indicating an 80.7% upside potential, supported by upward revisions in earnings estimates.
The 80.7% upside potential signals strong growth expectations for Molecular Partners AG, while positive earnings revisions suggest imminent stock price appreciation.
The MP0533 phase 1/2a dose escalation study shows an acceptable safety profile, with initial signs of antileukemic and pharmacodynamic activity.
Positive results from MP0533's study indicate potential for effective leukemia treatment, which could boost company valuation and stock performance if it progresses successfully.
Frequently Asked Questions About MOLN Stock
What is Molecular Partners AG's (MOLN) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Molecular Partners AG (MOLN) has a median price target of $9.52. The highest price target is $16.83 and the lowest is $4.97.
Is MOLN stock a good investment in 2025?
According to current analyst ratings, MOLN has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MOLN stock?
Wall Street analysts predict MOLN stock could reach $9.52 in the next 12 months. This represents a 91.6% increase from the current price of $4.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Molecular Partners AG's business model?
The company operates as a clinical-stage biotechnology firm, generating revenue through the development of innovative therapeutics such as designed ankyrin repeat proteins (DARPins) aimed at treating cancer and viral diseases. It engages in licensing and collaboration agreements with major pharmaceutical companies, allowing it to leverage its specialized platforms for drug development.
What is the highest forecasted price for MOLN Molecular Partners AG?
The highest price target for MOLN is $16.83 from at , which represents a 238.7% increase from the current price of $4.97.
What is the lowest forecasted price for MOLN Molecular Partners AG?
The lowest price target for MOLN is $4.97 from at , which represents a 0.1% increase from the current price of $4.97.
What is the overall MOLN consensus from analysts for Molecular Partners AG?
The overall analyst consensus for MOLN is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $9.52.
How accurate are MOLN stock price projections?
Stock price projections, including those for Molecular Partners AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.